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Abstract
Objectives—To determine opioid prescribing practices to the orthopaedic trauma (OT) 
population at one level I trauma center.
Design—A retrospective study of discharge prescriptions for adult OT patients. Prescription 
details, injury burden, and patient demographics were abstracted for patients from initial injury 
through 2 month follow up.
Setting—A busy level I trauma center.
Patients/Participants—Adult OT patients admitted over a 30-day period (n=110).
Intervention—All discharge and follow-up opioid prescriptions were recorded.
Main Outcome Measurements—Morphine milligram equivalents per day, Number of opioid 
prescriptions, type/dose of medication prescribed
Results—135 Discharge prescriptions were written for 110 patients with orthopaedic injuries 
during the review period (Table 1). All patients received opioids at the time of discharge (Table 2). 
The MMEs prescribed at the time of discharge was 114 mg (54–300 mg) for a mean of 7.21 days 
(2–36.7 days). While patients with pre-injury risk factors were prescribed discharge opioids for a 
similar duration (7.00 days, versus 7.30 days, p=0.81) than those without risk factors, they were 
prescribed significantly more MMEs than those without (130 versus 108, p<.05), and were more 
likely to receive ER/LA opioids than those without (42.11% versus 21.98%).
Conclusions—Pain management after orthopaedic trauma continues to be opioid-centric despite 
involving a population at risk. Further focus on prescriber and patient education, risk evaluation 
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with mitigation, guideline development, and comprehensive pain management strategies are 
warranted in the orthopaedic trauma population.
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INTRODUCTION
Opioid-based narcotics are commonly prescribed for pain control in orthopaedic surgery 
patients and have a high risk for abuse and dependence.1,2 In 2001, Joint Commission 
(JCHAO) introduced mandatory pain assessment standards in all patients and cited “pain is 
the fifth vital sign” as an example of a strategy for some clinical settings3. Concurrently, 
there was a massive marketing campaign by pharmaceutical companies promoting 
prescription opioids. This has resulted in the U.S. developing a largely pharmaceutical 
approach to pain management. The result is that the US consumes the majority of the 
world’s prescription opioids while representing less than 5% of the world’s population.4 
Concurrently, unintentional overdose deaths have risen sharply, largely due to an increase 
overdoses involving prescription opioids often obtained from a secondary non-medical 
source.5,6
Prescription opioid use now results in more deaths than cocaine and heroin combined each 
year.7 Of the medical specialties in the U.S., orthopaedic surgeons are the third highest 
prescribers of opioids.8 Studies have evaluated the prescribing habits of orthopaedic 
surgeons and the effect of opioids postoperatively during various procedures.9,10 Patients 
with hip and ankle fractures treated in the Netherlands who did not receive postoperative 
opioids have been shown to have less postoperative pain and more satisfaction than patients 
with the same injuries in the U.S. who received opioids.9,11 During this same time period, 
basic science studies have negatively influenced US Orthopaedic Surgeons attitudes about 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in the setting of healing fractures, 
despite a lack of good clinical contraindication data and widespread use 
internationally.9,11–13 This ushered in an era of opioid monotherapy for orthopaedic injuries. 
On the contrary, opioids are associated with worse clinical outcomes in patients with 
occupational musculoskeletal disorders and patients undergoing total knee arthroplasty, 
reverse shoulder arthroplasty, and spine surgery.1,10,14,15
Physicians and Non-physician providers who manage orthopaedic trauma patients should be 
particularly well-versed in risk assessment and mitigation strategies, since many in this 
population are at greater risk.16–20 Massey et al. evaluated patients with a positive 
toxicology screen at the time of injury and found these patients to be at an increased risk for 
prolonged opioid use compared to those whose toxicology screen was negative.17 In 
evaluating additional pre-injury risk factors, Helmerhorst et al. found patients with anxiety 
prior to their surgery had greater pain scores and post-injury disability compared to those 
without anxiety.20 The study also found patients who continued to use opioids 1 to 2 months 
past their date of surgery had more disability and psychological distress than those who were 
no longer taking opioids.20 Patients with pre-injury opioid use are more likely to have 
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multiple opioid prescribers postoperatively and continue opioids for a longer duration 
following surgery.17,18 Substance abuse is another important risk factor for subsequent abuse 
of prescription opioids.13 Moreover, rates of iatrogenically-induced addiction show wide 
variation and predictability in the literature21–27 and increase with duration of exposure.28–31
Over the course of the past 20 years, Extended Release/Long Acting opioids like Oxycontin 
gained widespread use based on retracted claims of improved safety32, and unsubstantiated 
claims of improved efficacy versus short acting opioids.33–38 “Tamper resistant” extended 
release opioids were developed to curb abuse and misuse.32,39 It has now been demonstrated 
that these drugs can still be abused and remain highly addictive.40,41 Subsequent studies 
have not proven that extended release narcotics have greater efficacy than immediate 
release.33–38 Despite these data and the FDA black label warning42 in 2001 (updated in 
2015), ER/LA opioids are still commonly prescribed. Another system implemented to 
identify patients at risk for opioid abuse and misuse are prescription drug monitoring 
programs.43 Despite these efforts, the opioid epidemic continues to escalate, and a more 
comprehensive and efficient method to stratify and identify patients at risk for 
nontherapeutic opioid use is needed.44 The purpose of this study is to determine the opioid 
prescribing practices in the orthopaedic trauma population at a single institution.
METHODS
Setting and Patients
A retrospective study of prescribing patterns at the time of inpatient discharge in adult 
orthopaedic trauma patients (including operative and nonoperative cases) admitted to a level 
1 trauma center over a one-month period was conducted. Patients were discharged by either 
the Orthopaedic Trauma team or the Trauma Critical Care team. This audit was limited to 
one month, since it was conducted as a basis for a series of multi-disciplinary process 
improvements planned across the health system gradually over the next several months to 
years. All Orthopaedic Trauma discharges were conducted at the single Level 1 trauma 
center. The expansive health system (15 hospitals, 6 freestanding Emergency Departments 
(EDs), 30 Urgent Cares, and 350 clinics) on a common electronic medical record system 
was utilized to capture follow-up data on discharged patients. This is possible because the 
healthcare system maintains the dominant and growing footprint in a highly consolidated 
healthcare market. More importantly, the system scores highly in markers of patient loyalty 
like patient satisfaction and employee satisfaction45–47. Within system follow-up rates are 
quite high in both data analytic reviews and retrospective studies48–51.
Data Collection and Measures
Discharge prescription details to include prescriber, drug, dose, and duration were recorded. 
The same details were recorded for subsequent outpatient prescriptions up to two months 
following discharge20,52. In addition, demographic information, including gender, age, and 
employment status, were abstracted from the electronic medical record into REDCap 
(Vanderbilt University, Nashville, TN)53.
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Relevant medical information abstracted included mechanism of injury, injury severity score 
(ISS), length of stay, and toxicology results. Daily morphine milligram equivalent (MME) 
dose was calculated for each prescription.54
We established a panel of subject matter experts from a diverse background of health care 
and public health to conduct an evidence based review to identify objective risk factors for 
abuse, misuse, and diversion.39 This panel included members from Public Health, 
Orthopaedic Trauma, Addiction Medicine, Poison Control, Pain Management, Emergency 
Medicine, Internal Medicine, Trauma/Critical Care, and Information Technology55. Risk 
factors were further limited to those that were objectively searchable in the electronic 
medical record. Included risk factors were: 1) current opioid prescription with >50% 
remaining expected (“early refills”); 2) 2+ visits to the ED or Urgent Care with onsite 
treatment with opioids within the 30 days prior to the prescription; 3) 3+ prescriptions for 
opioids within the 30 days prior to the prescription; 4) any previous presentation for opioid 
overdose within the EMR; and 5) any positive screen for blood alcohol content (BAC), 
cocaine, or marijuana within the EMR.56–65 We conducted focus group style interviews with 
prescribers to determine appropriateness of the thresholds of the risk factors. All urgent care 
and ED visits, as well as pre- and post-injury prescription information, was abstracted 
retrospectively from the EMR. Missing data was less of a concern, since limited our 
variables to orders/prescriptions, diagnostic codes, and lab results that are consistently and 
reliably documented within the EMR. Based on these risk factors, if a patient had one or 
more, they were classified as “at risk”.
Data Analysis
Descriptive statistics were used to characterize the patient population and rates of opioid 
prescribing. T-tests were performed to determine if a difference in means existed for MME, 
duration of prescriptions, and number of prescriptions between patients receiving extended 
release vs. immediate release; as well as between “at risk” patients and patients without risk 
factors. Z-tests were used to detect a difference in proportion of “at risk” patients between 
those prescribed extended release vs. immediate release opioids. A significance level of 0.05 
was used. Statistical analysis was performed using SAS.
RESULTS
135 Discharge prescriptons were written for 110 patients withorthopaedic injuries during the 
review period (Table 1). All patients received opioids at the time of discharge (Table 2). The 
MMEs prescribed at the time of discharge was 114 mg (54–300 mg) for a mean of 7.21 days 
(2–36.7 days). There was no difference in the mean MMEs prescribed at discharge between 
patients who underwent surgery and those that did not (117 mg versus 113 mg, p=0.70).
The most prevalent age group was 30–49 (28.2%) years. The most common mechanism of 
injury was a motor vehicle collision (32.7%). The mean ISS was 11.2. 53% of patients had 
at least one operative injury. ISS was not significantly different between patients treated 
operatively vs. nonoperatively. Fifty percent of the patients were unemployed at their time of 
injury, which is a risk factor for opioid overdose.63 The mean hospital length of stay was 5.4 
days (range 1–25 days).
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At the time of admission, 33.6% received a toxicology screen. 16.4% of all presenting 
patients (almost half of those who were tested) had a positive BAC or toxicology screen for 
cocaine or marijuana (Table 3).
Patients who were prescribed extended-release oxycodone had a mean of 1.74 opioid 
prescriptions provided to them at the time of discharge, compared to 1.09 for those who did 
not (p= 0.53). Patients who were prescribed extended-release oxycodone at the time of 
discharge were prescribed significantly more MMEs than those who did not (149 mg versus 
107 mg, p<.05). There was no difference in the ISS of patients who received extended-
release oxycodone and those who didn’t (12.3 versus 12.4, p=0.971). These ER/LA 
prescriptions were for a significantly longer duration after discharge (16.3 days versus 5.18 
days, p<.05).
Twenty-five percent of the OT patients met some criteria that indicate risk for misuse, abuse, 
or diversion of prescription opioids upon admission for the baseline injury (Table 4). While 
patients with pre-injury risk factors were prescribed discharge opioids for a similar duration 
(7.00 days, versus 7.30 days, p=0.81) than those without risk factors, they were prescribed 
significantly more MMEs than those without (130 versus 108, p<.05), and were more likely 
to receive ER/LA opioids than those without (42.11% versus 21.98%).
During the 2 months of follow-up, 42.7% received at least 1 additional prescription for 
narcotics. The most commonly prescribed opioids during follow-up visits were 
hydrocodone-acetaminophen (36.4%), followed by oxycodone-acetaminophen (12.7%) and 
other opioids (2.7%). There was a mean of 0.37 visits per patient (range 0–4 visits) in which 
an opioid prescription was provided during the follow-up period. Patients were provided an 
average of 1.1 opioid prescriptions at their follow-up visit (range 1–4 prescriptions). The 
mean MMEs prescribed per patient during the follow-up window was 99.2 (0–555). Of 
patients that received a follow-up prescription, those with pre-injury risk factors received 
significantly more MMEs during their follow-up than those who did not (215 versus 79.5, 
p<.05). The opioid prescriptions they received during their follow-up visits were also for a 
significantly longer duration (11.8 days versus 4.37 days, p<.05). There was no difference in 
the number of prescriptions provided at follow-up between patients who received extended-
release oxycodone at the time of discharge and those who did not (1.17 versus 1.1, p= 0.72). 
The difference in the MMEs provided at follow-up between patients who receive extended-
release oxycodone at the time of discharge and those who did not was not statistically 
significant (142 versus 89.7, p=0.09). However, the opioid prescriptions they received during 
their follow-up visits were for a significantly longer duration (11.4 days versus 4.13 days, 
p<.05). The final opioid prescription was provided a mean of 1.82 weeks (range 0–13.3) 
post-discharge. Another 9.1% of patients demonstrated at-risk behavior56–65 during the two-
month follow-up.
DISCUSSION
Until very recently, there has been very little education to prescribers on pain management 
strategies66–68 and risk other than the opioid monotherapy that has dominated the past two 
decades. Wide variance in prescribing practices to include the use of long-acting opioids 
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have been anecdotally noted in the trauma population, but publications in this area are 
lacking. Despite growing evidence of the link between prescription opioids and worse 
functional outcome, addiction, and even death, there has been a lack of translation of these 
data to clinical practice. Unfortunately, there has been limited education in the trauma 
community in the areas of risk mitigation, and non-pharmaceutical strategies for pain 
management.
Prescribers that are discharging orthopaedic trauma patients need to be aware that this is an 
at-risk population17,18. Risk Evaluation and Mitigation Strategies (REMS) should be 
employed in these patients.69,70 Over 25% of the patients in this study had risk factors for 
abuse, misuse, or diversion of prescription opioids at the time of injury and were prescribed 
alarmingly high MMEs at the time of discharge. Patients who were prescribed extended-
release oxycodone at the time of discharge received significantly more MMEs.
In the current study, almost 8% of this patient population had an existing/active opioid 
prescription with greater than 50% of the prescription remaining at the time of injury. Four-
percent of the patients had received 3 or more opioid prescriptions within the 30 days prior 
to admission and 2% of the patients had 2 or more on-site emergency department or urgent 
care visits resulting in administration of opioids. Patients in this study with pre-injury risk 
factors received significantly more MMEs at the time of discharge, and during their follow-
up visits than patients who did not. This is not only of concern because these are patients 
who will be at high risk of continued nontherapeutic opioid use after injury, but pre-injury 
opioid use has been associated with poor outcomes across multiple orthopaedic 
subspecialties.1,14,15
In evaluating orthopaedic trauma patients at the time of admission, Massey et al. found 72% 
of the patients to have either a positive BAC or toxicology screen.17 This is of importance 
for multiple reasons. Patients with a positive toxicology screen on admission have been 
found to be at an increased risk for prolonged opioid use.17 Nineteen percent of the patients 
in this study had either a positive BAC or toxicology screen for cocaine or marijuana on 
admission. This group of patients is at high risk for misuse or abuse of prescription opioids 
and strategies to mitigate this risk should be undertaken by prescribers throughout the 
inpatient stay and at the time of discharge. Clinical decision support built within the 
electronic medical record to identify risk for abuse or misuse would be a beneficial step to 
engaging in primary prevention by employing multimodal strategies and cognitive 
behavioral therapy to appropriately reduce dose and duration of opioid prescriptions.71,72
Furthermore, recognition that certain mental illnesses are risk factors for nontherapeutic 
opioid use73 can help physicians direct more holistic treatment for these patients. Twenty-
two percent of patients in this study had been diagnosed with anxiety at some point, and 
twenty-one percent of patients had been diagnosed with depression.
In this study of orthopaedic trauma patients who received a prescription opioid at the time of 
discharge, oxycodone-acetaminophen was the most commonly prescribed opioid. Almost 
one fifth of the patients in this study received a prescription for extended-release oxycodone 
at the time of discharge. The majority of these patients received an immediate release opioid 
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as well. Patients discharged with extended-release oxycodone averaged 149 MMEs and 
received 141 MMEs per day during their follow-up visits. These are both well above risk 
thresholds for overdose5,74 and the maximum of 90 MMEs per day the Centers for Disease 
Control and Prevention recommends for treating chronic pain.75 Despite the attempt to 
reduce the danger of OxyContin® with abuse-deterrent formulations, it is now clear that this 
remains a highly addictive drug with abuse potential as well as potentially devastating 
adverse effects.40,41 The manufacturer of OxyContin® has paid over $600 million in fines 
for inappropriately marketing the drug as non-addictive and having less potential for 
abuse.32 The majority of the literature citing the benefit and decreased abuse potential of 
extended release OxyContin® was funded by the manufacturer of the drug.76–79 There has 
been a slight slowing of the increase in opioid related deaths in some states that is thought to 
be a result of stricter policies and regulations rather than the reformulation of 
OxyContin®.80–83 The Academy of Orthopaedic Surgeons (AAOS) issued an information 
statement recommending against the use of extended-release opioids for the treatment of 
acute pain84. In the current study, all of the extended-release opioid prescriptions were 
written by non-orthopaedic prescribers. This study highlights that despite the risks 
associated with extended-release opioids, they are still being prescribed at alarming rates in 
an at-risk population in an opioid monotherapy regimen.
In addition to opioid prescriptions at the time of discharge, 43% of patients received an 
additional opioid prescription during the follow-up period. Care must be taken when 
prescribing opioids during follow-up visits, as opioid use one to two months past the date of 
surgery is associated with increased disability and psychological distress.20 Data suggests 
that 50% of patients taking prescription opioids for 3 months will continue to take them at 5 
years.28 During the 2 month follow-up period of this study, an additional 9% of patients 
developed new risk criteria.
Unfortunately, there are no current clinical practice guidelines on pain management in 
Orthopaedic Surgery to include Orthopaedic Trauma85. Some guidelines do exist, like the 
CDC guidelines for chronic pain75 and guidelines from other specialties and organizations86. 
Acute post-injury or post-surgery guidelines for pain management are scarce and 
demonstrate significant research gaps87,88.
There are several limitations of this study. 1. It is retrospective in nature and limited to 
prescriptions provided within our healthcare system. The primary focus of the study is 
discharge prescriptions which makes it generalizable to any busy level 1 trauma center. Due 
to the large size of the health system in such a consolidated market, the follow-up data on 
prescriptions has some validity. 2. The sample size is small and limited to patients admitted 
over a 30-day period and followed for two-months after injury. This audit of prescribing 
practices was limited to one month to define the problem and target gaps for improvement. 
Subsequent to the audit, our health system began a series of interventions as an iterative 
improvement process that is still ongoing toward safer prescribing and appropriate, 
comprehensive pain management. 3. Patients who were previously prescribed opioids for 
cancer pain were not excluded. This is a patient population that is known to be prescribed 
higher MMEs per day than the general population. The number of cancer patients however 
should be quite small.
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Management of pain following orthopaedic trauma is complex, and requires that surgeons be 
attuned to need to balance patient safety with the need to adequately and appropriately 
manage pain. Our results show that twenty-five percent of orthopaedic trauma (OT) patients 
have risk factors for abuse, misuse, or diversion of prescription opioids at baseline injury. An 
additional 9% of orthopaedic trauma patients became at-risk in the follow-up time period. 
These data suggest that a move away from opioid monotherapy into a more comprehensive 
pain management strategy to include multimodal pain management, cryotherapy, cognitive 
behavioral therapy71,72 and others is needed. Orthopaedic practices and hospitals should 
develop standardized opioid prescribing protocols and encourage continuing medical 
education on opioid safety and appropriate use for physicians and non-physician providers 
that prescribe opioids.89 To our knowledge, this study is the first to quantitatively evaluate 
the discharge prescribing practices in an at-risk orthopaedic trauma population. These data 
are essential as the first step in process improvement for safer opioid prescribing. 
Improvements should include the use of REMS, development and utilization of prescribing 
guidelines, and understanding of non-pharmaceutical strategies for pain management. 
Further, these data should compel clinicians to consider utilizing MME calculators and 
checking the state Prescription Drug Monitoring Database when prescribing opioids and to 
eliminate the use of ER/LA opioids for acute injury/pain. It also warrants a re-evaluation of 
the risk of Non-Steroidal Antiinflammatory Drugs versus opioids in the setting of 
musculoskeletal injury.
CONCLUSION
Pain management after orthopaedic trauma continues to be opioid-centric despite involving a 
population at risk. Further focus on prescriber and patient education, risk evaluation with 
mitigation, guideline development, and comprehensive pain management strategies are 
warranted in the orthopaedic trauma population.
Acknowledgments
PRIMUM Group (in alphabetical order):
Michael Beuhler, MD, Poison Information Center; Carolinas HealthCare System, Charlotte, NC, USA
Michael J. Bosse, MD, Department of Orthopaedic Surgery; Carolinas HealthCare System, Charlotte, NC
Emily Gerkin, Department of Orthopaedic Surgery; Carolinas HealthCare System, Charlotte, NC
Michael Gibbs, MD, Department of Emergency Medicine; Carolinas HealthCare System, Charlotte, NC, USA
Christopher Griggs, MD, Department of Emergency Medicine; Carolinas HealthCare System, Charlotte, NC, USA
Steven Jarrett, PharmD, Patient Safety; Carolinas HealthCare System, Charlotte, NC, USA
Daniel Leas, MD, Department of Orthopaedic Surgery; Carolinas HealthCare System, Charlotte, NC
Michael Runyon, MD, Department of Emergency Medicine; Carolinas HealthCare System, Charlotte, NC, USA
Animita Saha, MD, Department of Internal Medicine; Carolinas HealthCare System, Charlotte, NC, USA
Sharon Schiro, PhD, Department of Orthopaedic Surgery; Carolinas HealthCare System, Charlotte, NC
Bradley Watling, MD, Emergency Medicine Physicians; Carolinas HealthCare System, Charlotte, NC, USA
Ruder et al. Page 8
J Orthop Trauma. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Stephen Wyatt, DO, Adult Psychiatry; Carolinas HealthCare System, Charlotte, NC, USA
Source of Funding: All authors are investigators on a grant from the Centers for Disease Control and Prevention 
(CE14-004 Award Number CE002520) and an internal grant from the Carolinas Trauma Network Research Center 
of Excellence for this work. RBS is currently receiving grants from Department of Defense, AO Foundation, and 
Orthopaedic Trauma Association. JRH is on the board of directors for Limb Lengthening and Reconstruction 
Society, is a consultant for Acumed, and is on the speaker’s bureau for Smith Nephew. MJB is currently receiving a 
grant from the Department of Defense. MR is currently receiving a grant from NIH and royalties from UpToDate.
References
1. Zywiel MG, Stroh DA, Lee SY, Bonutti PM, Mont MA. Chronic opioid use prior to total knee 
arthroplasty. J Bone Joint Surg Am. Nov 2; 2011 93(21):1988–1993. [PubMed: 22048093] 
2. Morris BJ, Mir HR. The opioid epidemic: Impact on orthopaedic surgery. J Am Acad Orthop Surg. 
2015; 23(5):267–271. [PubMed: 25911660] 
3. Joint Commission on Accreditation of Healthcare Organizations. Pain: Current Understanding of 
Assessment, Management, and Treatments. Washington, DC: National Pharmaceutical Council, 
INC and Joint Commission on Accreditation of Healthcare Organizations; 2001. 
4. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and 
complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. Mar; 
2008 11(2 Suppl):S63–88. [PubMed: 18443641] 
5. Bohnert ASB, Valenstein M, Bair MJ, et al. Association Between Opioid Prescribing Patterns and 
Opioid Overdose-Related Deaths. JAMA. 2011; 305(13):1315–1321. [PubMed: 21467284] 
6. Substance Abuse and Mental Health Services Administration. Results from the 2010 National 
Survey on Drug Use and Health: Summary of National Findings. U.S. Department of Health and 
Human Services; 2011. 
7. Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 
Jul; 2012 15(3 Suppl):ES9–38. [PubMed: 22786464] 
8. Volkow ND, McLellan TA, Cotto JH. Characteristics of opioid prescriptions in 2009. JAMA. 2011; 
305(13):1299–1300. [PubMed: 21467282] 
9. Lindenhovius AL, Helmerhorst GT, Schnellen AC, Vrahas M, Ring D, Kloen P. Differences in 
prescription of narcotic pain medication after operative treatment of hip and ankle fractures in the 
United States and The Netherlands. J Trauma. Jul; 2009 67(1):160–164. [PubMed: 19590328] 
10. Kidner CL, Mayer TG, Gatchel RJ. Higher opioid doses predict poorer functional outcome in 
patients with chronic disabling occupational musculoskeletal disorders. J Bone Joint Surg Am. 
Apr; 2009 91(4):919–927. [PubMed: 19339577] 
11. Helmerhorst GT, Lindenhovius AL, Vrahas M, Ring D, Kloen P. Satisfaction with pain relief after 
operative treatment of an ankle fracture. Injury. Nov; 2012 43(11):1958–1961. [PubMed: 
22901424] 
12. Kurmis AP, Kurmis TP, O’Brien JX, Dalen T. The effect of nonsteroidal anti-inflammatory drug 
administration on acute phase fracture-healing: a review. J Bone Joint Surg Am. May 2; 2012 
94(9):815–823. [PubMed: 22552671] 
13. Dodwell E, Latorre J, Parisini E, et al. NSAID exposure and risk of nonunion: a meta-analysis of 
case-control and cohort studies. Calcif Tissue Int. 2010; 87(3):193–202. [PubMed: 20552333] 
14. Morris BJ, Laughlin MS, Elkousy HA, Gartsman GM, Edwards TB. Preoperative opioid use and 
outcomes after reverse shoulder arthroplasty. J Shoulder Elbow Surg. Jan; 2015 24(1):11–16. 
[PubMed: 25037063] 
15. Lee D, Armaghani S, Archer KR, et al. Preoperative Opioid Use as a Predictor of Adverse 
Postoperative Self-Reported Outcomes in Patients Undergoing Spine Surgery. J Bone Joint Surg 
Am. Jun 4.2014 96(11):e89. [PubMed: 24897746] 
16. Levy RS, Hebert CK, Munn BG, Barrack RL. Drug and alcohol use in orthopedic trauma patients: 
a prospective study. J Orthop Trauma. 1996; 10(1):21–27. [PubMed: 8926551] 
17. Massey GM, Dodds HN, Roberts CS, Servoss TJ, Blondell RD. Toxicology screening in 
orthopedic trauma patients predicting duration of prescription opioid use. Journal of Addictive 
Diseases. 2005; 24(4):31–41. [PubMed: 16368655] 
Ruder et al. Page 9
J Orthop Trauma. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
18. Morris BJ, Zumsteg JW, Archer KR, Cash B, Mir HR. Narcotic Use and Postoperative Doctor 
Shopping in the Orthopaedic Trauma Population. J Bone Joint Surg Am. Aug 6; 2014 96(15):
1257–1262. [PubMed: 25100772] 
19. Holman JE, Stoddard GJ, Higgins TF. Rates of prescription opiate use before and after injury in 
patients with orthopaedic trauma and the risk factors for prolonged opiate use. J Bone Joint Surg 
Am. Jun 19; 2013 95(12):1075–1080. [PubMed: 23783203] 
20. Helmerhorst GT, Vranceanu AM, Vrahas M, Smith M, Ring D. Risk factors for continued opioid 
use one to two months after surgery for musculoskeletal trauma. J Bone Joint Surg Am. Mar 19; 
2014 96(6):495–499. [PubMed: 24647506] 
21. Fishbain DA, Rosomoff H, Rosomoff R. Drug abuse, dependence, and addiction in chronic pain 
patients. Clin J Pain. 1992; 8:77–85. [PubMed: 1633386] 
22. Hoffmann N, Olofsson S, Salen B, Wickstrom L. Prevalence of abuse and dependence in chronic 
pain patients. Int J Addict. 1995; 30:919–927. [PubMed: 7558484] 
23. Kouyanou K, Pither C, Wessely S. Medication misuse, abuse, and chronic dependence in chronic 
pain patients. J Psychosom Res. 1997; 43:497–504. [PubMed: 9394266] 
24. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic 
pain patients: Clinical criteria, incidence, and predictors. The Clinical Journal of Pain. 1997; 13(2):
150–155. [PubMed: 9186022] 
25. Katz N, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in 
patients receiving long-term opioid therapy. Anesth Analg. 2003; 97:1097–1102. [PubMed: 
14500164] 
26. Reid M, Engles-Horton L, Weber M, et al. Use of opioid medications for chronic non-cancer pain. 
J Gen Intern Med. 2002; 17:173–179. [PubMed: 11929502] 
27. Michna E, Jamison R, Pham L, et al. Urine toxicology screening among chronic pain patients on 
opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007; 23:173–179. 
[PubMed: 17237667] 
28. Martin B, Fan M, Edlund M, DeVries A, Braden J, Sullivan M. Long-term chronic opioid therapy 
discontinuation rates from the TROUP study. J Gen Intern Med. 2011; 26:1450–1457. [PubMed: 
21751058] 
29. Turk, DC., Okifuji, A. Pain terms and taxonimies. In: Fishman, S.Ballantyne, JC., Rathmell, J., 
editors. Bonica’s Management of Pain. 4th. Lippincott Williams and Wilkins; 2010. p. 14-23.
30. Braden J, Fan M, Edlund M, Martin B, DeVries A, Sullivan M. Trends in use of opioids by 
noncancer pain type 2000–2005 among Arkansas Medicaid and HealthCore enrollees: results from 
the TROUP study. J Pain. 2008; 9(11):1026–1035. [PubMed: 18676205] 
31. Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. 
Clin J Pain. 2008; 24(6):521–527. [PubMed: 18574361] 
32. Meier B. In guilty plea, OxyContin maker to pay $600 million. The New York Times. May 
10.2007 2007; Business Day. 
33. Hale M, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled release versus 
immediate-release oxycodone: randomized, double-blind evaluation in chronic back pain. Clin J 
Pain. 1999; 15:179–183. [PubMed: 10524470] 
34. Kaplan R, Parris W, Citron M, et al. Comparison of controlled-release and immediate-release 
oxycodone in cancer pain. J Clin Oncol. 1998; 16:3230–3237. [PubMed: 9779696] 
35. Staumbaugh J, Reder R, Staumbaugh M, et al. Double-blind, randomized comparison of the 
analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in 
cancer pain patients. J Clin Pharmacol. 2001; 41:500–506. [PubMed: 11361046] 
36. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain. 
1997; 73:37–45. [PubMed: 9414055] 
37. Mucci-LoRusso P, Berman B, Silberstein P, et al. Controlled-release oxycodone compared with 
controlled-release morphine in treatment of cancer pain: a randomized, double-blind, parallel-
group study. Eur J Pain. 1998; 2:239–249. [PubMed: 15102384] 
38. Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety 
and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients 
with cancer pain. J Clin Oncol. 1998; 16:3222–3229. [PubMed: 9779695] 
Ruder et al. Page 10
J Orthop Trauma. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
39. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid 
abuse-deterrent formulations. The Clinical Journal of Pain. 2007; 23(8):648–660. [PubMed: 
17885342] 
40. Novak S. Comment on the United States Food and Drug Administration Docket FDA-2013-
D-0045. Jan.2013 2013. 
41. Cicero TJ, Ellis MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in 
the United States: Lessons Learned From OxyContin. JAMA Psychiatry. May; 2015 72(5):424–
430. [PubMed: 25760692] 
42. Administration USFaD. , editor. US Food and Drug Administration. OxyContin Medication Guide. 
2015. 
43. Green TC, Mann MR, Bowman SE, et al. How Does Use of a Prescription Monitoring Program 
Change Medical Practice? Pain Medicine. 2012; 13:1314–1323. [PubMed: 22845339] 
44. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health 
Statistics and Quality. Results from the 2013 National Survey on Drug Use and Health. Rockville, 
MD: US Department of Health and Human Services; 2013. 
45. Platonova E, Kennedy K, Shewchuk R. Understanding patient satisfaction, trust, and loyalty to 
primary care physicians. Med Care Res Rev. 2008; 65(6):696–712. [PubMed: 18723450] 
46. Kessler D, Mylod D. Does patient satisfaction affect patient loyalty? Health Care Qual Assur. 
2011; 24(4):266–273.
47. Atkins P, Marshall B, Javalgi R. Happy employees lead to loyal patients. Survey of nurses and 
patients shows a strong link between employee satisfaction and patient loyalty. J Health Care 
Mark. 1996; 16(4):14–23.
48. Carolinas HealthCare System. Advanced Analytics. 2016. http://www.carolinashealthcare.org/da2. 
Accessed February 12, 2016
49. Lack WD, Karunakar MA, Angerame MR, et al. Type III open tibia fractures: immediate antibiotic 
prophylaxis minimizes infection. J Orthop Trauma. Jan; 2015 29(1):1–6. [PubMed: 25526095] 
50. Large T, Kellam J, Bosse M, Sims S, Althausen P, Masonis J. Locked plating of supracondylar 
periprosthetic femur fractures. J Arthroplasty. 2008 Sep; 23(6 Suppl):115–120. [PubMed: 
18617358] 
51. Haines N, Lack WD, Seymour R, Bosse M. Defining the lower limit of a “critical bone defect” in 
open diaphyseal tibia fractures. J Orthop Trauma. 2016 May; 30(5):e158–163. [PubMed: 
27101166] 
52. Vranceanu A, Bachoura A, Weening A, Vrahas M, Smith R, Ring D. Psychological factors predict 
disability and pain intensity after skeletal trauma. J Bone Joint Surg Am. 2014; 96(3):e20. 
[PubMed: 24500592] 
53. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture 
(REDCap) – A metadata-driven methodology and workflow process for providing translational 
research informatics support. J Biomed Inform. 2009 Apr; 42(2):377–381. [PubMed: 18929686] 
54. Centers for Disease Control and Prevention. [Accessed September 13, 2016] Calculating total daily 
dose of opioids for safer dosage. Available at: https://www.cdc.gov/drugoverdose/pdf/
calculating_total_daily_dose-a.pdf
55. Seymour R, Leas D, Wally M, Hsu J, Group P. Prescription reporting with immediate medication 
utilization mapping (PRIMUM): development of an alert to improve narcotic prescribing. BMC 
Medical Informatics and Decision Making. 2016; 16(111)
56. Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN. Effect of a centralized 
prescription network on inappropriate prescriptions for opoid analgesics and benzodiazepines. 
CMAJ. Nov 6; 2012 184(16):E852–E856. [PubMed: 22949563] 
57. Yang Z, Wilsey B, Bohm M, et al. Defining risk of prescription opioid overdose: pharmacy 
shopping and overlapping prescriptions among long-term opioid users in medicaid. J Pain. May; 
2015 16(5):445–453. [PubMed: 25681095] 
58. Mack KA, Zhang K, Paulozzi L, Jones C. Prescription practices involving opioid analgesics among 
Americans with Medicaid, 2010. J Health Care Poor Underserved. Feb; 2015 26(1):182–198. 
[PubMed: 25702736] 
Ruder et al. Page 11
J Orthop Trauma. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
59. Grover CA, Garmel GM. How Do Emergency Physicians Interpret Prescription Narcotic History 
When Assessing Patients Presenting to the Emergency Department with Pain? Perm J. 2012; 
16(4):32–36. [PubMed: 23251114] 
60. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. Sep; 2012 43(4):283–289. 
[PubMed: 23127678] 
61. Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances 
and risk of drug overdose death. Pain Medicine. 2012; 13:87–95. [PubMed: 22026451] 
62. Colburn JL, Jasinski DR, Rastegar DA. Long-term opioid therapy, aberrant beaviors, and substance 
misuse: Comparison of patients treated by resident and attending physicians in a general medical 
clinic. Journal of Opioid Management. 2012; 8(3):153–160. [PubMed: 22798175] 
63. Johnson EM, Lanier WA, Merrill RM, et al. Unintentional prescription opioid-related overdose 
deaths: description of decedents by next of kin or best contact, Utah, 2008–2009. J Gen Intern 
Med. Apr; 2012 28(4):522–529. [PubMed: 23070654] 
64. Jones CM, Paulozzi LJ, Mack KA. Alcohol Involvement in Opioid Pain Reliever and 
Benzodiazepine Drug Abuse-Related Emergency Department Visits and Drug-Related Deaths–
United States, 2010. MMWR. 2014; 63(40):881–885. [PubMed: 25299603] 
65. Sehgal N, Manchikanti L, Smith HS. Prescription Opioid Abuse in Chronic Pain: A Review of 
Opioid Abuse Predictors and Strategies to Curb Opioid Abuse. Pain Physician. 2012; 15:ES67–
ES92. [PubMed: 22786463] 
66. Stanek J, Renslow M, Kalliainen L. The effect of an educational program on opioid prescription 
patterns in hand surgery: a quality improvement program. J Hand Surg Am. 2015; 40(2):341–346. 
[PubMed: 25542435] 
67. Katzman J, Comerci G, Landen MG, et al. Rules and values: a coordinated regulatory and 
educational approach to the public health crises of chronic pain and addiction. Am J Public Health. 
2014; 104(8):1356–1362. [PubMed: 24922121] 
68. Chiauzzi E, Trudeau K, Zacharoff K, Bond K. Identifying primary care skills and competencies in 
opioid risk management. J Contin Educ health Prof. 2011; 31(4):231–240. [PubMed: 22189986] 
69. US Food and Drug Administration. [Accessed January 26, 2017] Risk Evaluation and Mitigation 
Strategy (REMS) for extended-release and long-acting opioids. Available at: http://www.fda.gov/
Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm
70. Nelson L, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and 
mitigation strategy (REMS). JAMA. 2012 Aug; 308(5):457–458. [PubMed: 22851109] 
71. Vranceanu A, Barsky A, Ring D. Psychosocial aspects of disabling musculoskeletal pain. J Bone 
Joint Surg Am. 2009; 91(8):2014–2018. [PubMed: 19651964] 
72. Vranceanu A, Hageman M, Strooker J, ter Meulen D, Vrahas M, Ring D. A preliminary RCT of a 
mind body skills based intervention addressing mood and coping strategies in patients with acute 
orthopaedic trauma. Injury. 2015; 46(4):552–557. [PubMed: 25435134] 
73. Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and 
best practices. Pain Physician. Jul; 2012 15(3 Suppl):ES119–133. [PubMed: 22786451] 
74. Dunn KM, Saunders KW, Rutter CM, et al. Opioid Prescriptions for Chronic Pain and Overdose: A 
Cohort Study. Annals of Internal Medicine. 2010; 152:85–92. [PubMed: 20083827] 
75. Dowell D, Heaegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain – 
United States, 2016. MMWR. 2016; 65:1–49.
76. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin 
exposures in the National Poison Data System after introduction of extended-release oxycodone 
with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. Dec; 2013 22(12):1274–1282. 
[PubMed: 24123484] 
77. Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. Development and impact of 
prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend. May 1.2014 
138:1–6. [PubMed: 24613631] 
78. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a 
reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription 
opioid abusers. Drug Alcohol Depend. Jun 1.2014 139:9–17. [PubMed: 24721614] 
Ruder et al. Page 12
J Orthop Trauma. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
79. Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in 
reported deaths following the introduction of extended-release oxycodone (OxyContin) with an 
abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. Dec; 2014 23(12):1238–1246. 
[PubMed: 24916486] 
80. Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM. Abrupt decline in 
oxycodone-caused mortality after implementation of Florida’s Prescription Drug Monitoring 
Program. Drug Alcohol Depend. May 1.2015 150:63–68. [PubMed: 25746236] 
81. Tavernise S. Prescription Overdose Deaths in Florida Plunge After Tougher Measures, Report 
Says. 2014
82. Florida Health. E-FORCSE 2014–2015 Prescription Drug Monitoring Program Annual Report. 
Florida Health; Dec 1. 2015 2015
83. Chen L, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United 
States, 1999–2011. NCHS Data Brief. 2014; 166
84. American Academy of Orthopaedic Surgeons. Opioid use, misuse, and abuse in orthopaedic 
practice. 2015
85. American Academy of Orthopaedic Surgeons. [Accessed January 26, 2017] Clinical Practice 
Guidelines. Available at: http://www.aaos.org/guidelines/?ssopc=1
86. Franklin G. Opioids for chronic noncancer pain: A position paper of the American Academy of 
Neurology. Neurology. 2014; 83:1277–1284. [PubMed: 25267983] 
87. Chou R, Gordon DB, de Leon-Casasola O, et al. Management of Postoperative Pain: A Clinical 
Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia 
and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional 
Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016; 17(2):131–157. 
[PubMed: 26827847] 
88. Gordon D, De Leon-Casasola O, Wu C, Sluka K, Brennan T, Chou R. Research Gaps in Practice 
Guidelines for Acute Postoperative Pain Management in Adults: Findings from a Review of the 
Evidence for an American Pain Society Clinical Practice Guideline. J Pain. 2016; 17(2):158–166. 
[PubMed: 26719073] 
89. Parvizi J, Miller AG, Gandhi K. Multimodal pain management after total joint arthroplasty. J Bone 
Joint Surg Am. Jun 1; 2011 93(11):1075–1084. [PubMed: 21655901] 
Ruder et al. Page 13
J Orthop Trauma. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ruder et al. Page 14
Table 1
Demographic data for the orthopaedic trauma population.
Characteristics N (%)
Gender
 Male 70 (63.6%)
 Female 40 (36.4%)
Age
 18–29 28 (25.5%)
 30–49 31 (28.2%)
 50–64 22 (20.0%)
 65+ 24 (21.8)
Mechanism of Injury
 Motor vehicle crash 36 (32.7%)
 Fall <10 feet 24 (21.8%)
 Motorcycle crash 16 (15.5%)
 Other 10 (9.1%)
 Fall >10 feet 9 (8.2%)
Employment Status
 Employed 53 (48.2%)
 Unemployed 55 (50.0%)
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Table 2
Discharge medications for the orthopaedic trauma population.
Discharge Medication Percentage
oxycodone-acetaminophen 55.5
hydrocodone-acetaminophen 39.1
oxycodone 20.0
other opioids 3.64
benzodiazepines 2.73
morphine 1.81
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Table 3
Selected Risk Characteristics of adult orthopaedic trauma population upon admission, including toxicology 
results upon admission and history of mental health diagnoses
Risk Factor N (%)
Positive Toxicology Screen at admission for Alcohol, Marijuana, or Cocaine 18 (16.4%)
History of Positive Toxicology Screen in medical record for alcohol, marijuana, or cocaine 6 (5.5%)
Positive Alcohol 7 (6.4%)
Positive Opioids 6 (5.5%)
Positive Benzodiazepine 8 (7.3%)
Positive Marijuana 11 (10.0%)
Positive Anxiety 24 (21.8%)
Positive Depression 23 (20.9%)
Positive Bi-polar/schizophrenic 2 (1.82%)
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Table 4
Risk Characteristics of adult orthopaedic trauma population at discharge
Baseline Risk Characteristics N (%)
At risk baseline (met at least 1 trigger) 28 (25.5%)
Previous presentation for overdose 0 (0%)
3+ prescriptions within previous 30 days 4 (3.6%)
2+ on-site ED administration of opioids/benzodiazepines 2 (1.8%)
Existing/active prescription with >50% remaining 8 (7.3%)
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